By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Chinese molecular diagnostics firm Amoy Diagnostics today announced the Chinese State Food and Drug Administration has approved its KRAS mutation detection kit.

The Xiamen-based firm can now market its KRAS test for clinical use in China. In a statement, AmoyDx said the KRAS kit is the first molecular diagnostic assay to receive approval in China for use in personalized clinical testing in oncology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.